AHCO — AdaptHealth Corp.

AdaptHealth Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year Revenue: $3.245 billion, a decrease of 0.5% year-over-year; organic growth of 1.7%.
• Q4 Revenue: $846.3 million, down 1.2% year-over-year but up 1.7% organically.
• Adjusted EBITDA: $616.7 million for the full year; $163.1 million for Q4, with margins of 19.0% and 19.3% respectively.
• Free Cash Flow: $219.4 million for the year; $79.3 million for Q4.
• Net Debt: $1.694 billion, with a net leverage ratio of 2.75x, up from 2.68x in Q3.
• Legal Settlement: Included a $14.5 million legal settlement and a noncash goodwill impairment charge of $128 million related to the Diabetes Health segment.

2. Strategic Updates and Business Highlights

• Operational Transformation: Implemented a new operating model to enhance standardization and efficiency, contributing to patient census growth across various segments.
• Capitated Contract: Successfully closed the largest capitated contract in the industry, with smooth onboarding for the Mid-Atlantic states and plans for further expansions.
• Patient Census Growth: Achieved record patient census in sleep health, respiratory health, and wellness at home, with notable improvements in service delivery times.
• Acquisitions and Divestitures: Acquired a Hawaii-based HME provider, expanding to the 48th state, while divesting noncore assets to focus on strategic priorities.
• Technological Investments: Continued deployment of AI and digital engagement tools, enhancing service delivery and operational efficiency.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected net revenue of $3.44 billion to $3.51 billion, representing 6% to 8% growth over 2025.
• Adjusted EBITDA Guidance: Projected between $680 million to $730 million, with an expected margin improvement to approximately 20.3%.
• Free Cash Flow Guidance: Anticipated to be between $175 million to $225 million for the year.
• Q1 2026 Expectations: Revenue growth of 2% to 3% year-over-year, with expected adjusted EBITDA margin of approximately 16%.

4. Bad News, Challenges, or Points of Concern

• Legal Settlement Impact: The $14.5 million legal settlement and the $128 million goodwill impairment charge may raise concerns about past operational practices and financial health.
• Diabetes Health Segment: Despite improved retention rates, the segment experienced a decline in new starts and revenue, with expectations of flat growth in the near term.
• Debt Levels: The increase in net leverage ratio indicates ongoing concerns regarding debt management, although the company is focused on reducing debt.
• Market Competition: Potential challenges from smaller competitors in adapting to new CMS documentation requirements, which could impact market share.

5. Notable Q&A Insights

• Legal Settlement Clarification: Management confirmed the settlement was final and addressed a legacy issue, emphasizing improvements in compliance and operational controls.
• Capitated Agreements Pipeline: There is a strong interest in capitated agreements, with ongoing discussions, although the timeline for new contracts can be lengthy.
• Diabetes Segment Growth: Management is optimistic about future growth in the diabetes segment, with plans to expand the sales force to drive new starts.
• Infrastructure Investments: The company is on track with infrastructure readiness for new partnerships, with ongoing investments to support upcoming contract requirements.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of AdaptHealth's performance and outlook.